重症患者的抗血小板治疗:配对与贝叶斯网络Meta分析
该研究检索PubMed和Embase自建库至2017年6月的随机对照试验和观察性研究,评估抗血小板治疗对重症患者的效果。抗血小板治疗显著降低住院死亡率(RR 0.81,95%CI 0.68-0.97,P=0.025)、ICU死亡率(RR 0.78,95%CI 0.63-0.97,P=0.027)、呼吸窘迫综合征或急性肺损伤发生率(RR 0.73,95%CI 0.58-0.91,P=0.006)及脓毒症发生率(RR 0.81,95%CI 0.68-0.97,P=0.021)。预设亚组分析显示住院和ICU死亡率获益仅见于脓毒症患者(RR 0.71,95%CI 0.58-0.86,P<0.0001;RR 0.65,95%CI 0.49-0.86,P=0.002)。网络Meta分析显示阿司匹林和氯吡格雷较对照组降低住院死亡风险,SUCRA提示阿司匹林成为最佳抗血小板治疗的概率最高。
要点
- 抗血小板治疗使重症患者住院死亡率降低(RR 0.81,95%CI 0.68-0.97,P=0.025)。
- 抗血小板治疗使ICU死亡率降低(RR 0.78,95%CI 0.63-0.97,P=0.027)。
- 住院和ICU死亡率获益仅见于脓毒症患者(RR 0.71,95%CI 0.58-0.86;RR 0.65,95%CI 0.49-0.86)。
- 抗血小板治疗降低呼吸窘迫综合征或急性肺损伤发生率(RR 0.73,95%CI 0.58-0.91)及脓毒症发生率(RR 0.81,95%CI 0.68-0.97)。
- 网络Meta分析SUCRA提示阿司匹林成为最佳抗血小板治疗的概率最高。
适用人群与场景
- 重症患者,包括脓毒症患者;研究纳入随机对照试验和观察性研究。
研究设计与关键结果
- 研究类型为配对与贝叶斯网络Meta分析,检索PubMed和Embase自建库至2017年6月的随机对照试验和观察性研究。
- 抗血小板治疗 vs 对照组:住院死亡率RR 0.81(95%CI 0.68-0.97,P=0.025),ICU死亡率RR 0.78(95%CI 0.63-0.97,P=0.027),呼吸窘迫综合征或急性肺损伤发生率RR 0.73(95%CI 0.58-0.91,P=0.006),脓毒症发生率RR 0.81(95%CI 0.68-0.97,P=0.021)。
- 预设亚组分析按患者类型:住院死亡率获益仅见于脓毒症患者(RR 0.71,95%CI 0.58-0.86,P<0.0001),ICU死亡率获益仅见于脓毒症患者(RR 0.65,95%CI 0.49-0.86,P=0.002)。
- 网络Meta分析预测区间图显示,接受阿司匹林和氯吡格雷治疗的患者较对照组住院死亡风险更低。
- SUCRA排序概率图提示阿司匹林成为最低住院死亡率治疗的概率最高。
证据类型、等级与局限
- 证据类型:配对与贝叶斯网络Meta分析,纳入随机对照试验和观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为抗血小板治疗对重症患者的治疗有用,且该效应主要来自对脓毒症患者的作用。
- 网络Meta分析显示阿司匹林成为重症患者最佳抗血小板治疗的概率最高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Antiplatelet therapy is an attractive treatment option for critically ill patients. However, more evidence on the benefit of this therapy is required. We searched the PubMed and Embase databases from their inception to June 2017 for randomized controlled trials and observational studies that assess the effect of antiplatelet therapy in critically ill patients. Antiplatelet therapy resulted in significant decreases in hospital mortality (risk ratio [RR] 0.81, 95% confidence interval [CI], 0.68-0.97; P = 0. 025), intensive care unit (ICU) mortality (RR 0.78, 95% CI, 0.63-0.97; P = 0. 027), incidence of respiratory distress syndrome or acute lung injury (RR 0.73, 95% CI, 0.58-0.91; P = 0.006), and incidence of sepsis (RR 0.81, 95% CI, 0.68-0.97; P = 0.021). A predefined subgroup analysis according to patient type suggested that hospital mortality and ICU mortality benefits were seen only in septic patients (RR 0.71, 95% CI, 0.58-0.86; P < 0.0001) and (RR 0.65, 95% CI, 0.49-0.86; P = 0.002). By network meta-analysis, the predictive interval plot showed that patients treated with aspirin and clopidogrel had lower risk of hospital mortality as compared with control group. The assessment of rank probabilities using SUCRA plots indicated that aspirin presented the greatest likelihood of having lowest hospital mortality rate. The results of this meta-analysis suggest that antiplatelet therapy is useful for the treatment in critically ill patients, and this is primarily due to an effect on septic patients. Network meta-analysis shows that the probability of being the best antiplatelet therapy for critically ill patients was aspirin.
参考来源
- Du F, Jiang P, He S, et al. Antiplatelet Therapy for Critically Ill Patients: A Pairwise and Bayesian Network Meta-Analysis. Shock. 2018. PMID: 29176404. doi:10.1097/SHK.0000000000001057
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。